About Cavendish Impact Foundation
Cavendish Impact Foundation is a venture capital firm founded in 2017. It is primarily based out of Cooperstown, United States. As of May 2019, Cavendish Impact Foundation has invested in 18 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Series A round of Sandstone Diagnostics Overall, Cavendish Impact Foundation portfolio has seen 1 IPO and 2 acquisitions, namely Alto Neuroscience, Applied Therapeutics and StemoniX. LabCorp co-invest with Cavendish Impact Foundation, sharing a substantial percentage of its portfolio. Cavendish Impact Foundation has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Cavendish Impact Foundation's List of Top Investments
Cavendish Impact Foundation has a portfolio of 18 companies. Their most notable investments include Alto Neuroscience and Cleerly.Their portfolio spans across and United States. They have invested in Life Sciences, HealthTech, Enterprise Applications and 3 other sectors, across stages such as Series A stage. Here is the list of top investments by Cavendish Impact Foundation:
AI-driven drug discovery platform for neurological diseases based on patients biomarkers. The company's platform measures patients biomarkers like EEG and wearable data, behavioral patterns, genetics, and other factors to develop personalized psychiatric drugs. The company has pipeline of drugs including ALTO-100 for depression, ALTO-101 for neurodegenerative diseases, and more.
Key facts about Alto Neuroscience
- Founded Year: 2019
- Location: San Francisco (United States)
- Stage: Public
- Total Funding till date: $145M
- Employee Count: 87 as on Jul 31, 2026
- Investors: Perceptive Advisors, Commodore Capital and 36 Others
- Latest Funding Round: Post IPO, Mar 16, 2026, $*****
- Highlight: Public
2. Cleerly
Provider of an AI-driven platform for coronary artery disease assessment. The platform quantifies atherosclerosis by measuring plaque volume, composition, length, and location. It evaluates stenosis severity and determines the likely presence or absence of ischemia. The software aims to reduce the need for additional testing and enhance diagnostic confidence.
Key facts about Cleerly
- Founded Year: 2016
- Location: Denver (United States)
- Stage: Series C
- Total Funding till date: $578M
- Employee Count: 359 as on Jun 30, 2026
- Investors: T. Rowe Price, Fidelity Investments and 20 Others
- Latest Funding Round: Series C, Nov 19, 2024, $*****
- Highlight: Editors' Pick
Developer of drugs for the treatment of metabolic and cardiovascular diseases. The company's product line include AT-007 (govorestat), is a central nervous system-penetrant aldose reductase inhibitor designed for treating rare metabolic disorders such as galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase (CMT-SORD) deficiency, and PMM2-CDG. The company also develops AT-001 (caficrestat), for diabetic cardiomyopathy and diabetic peripheral neuropathy, along with preclinical efforts like AT-003 for diabetic retinopathy.
Key facts about Applied Therapeutics
- Founded Year: 2015
- Location: New York City (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2023
- Stage: Acquired
- Total Funding till date: $65.2M
- Employee Count: 10 - 49 as on Mar 01, 2026
- Investors: E Squared Capital, Collage Venture Partners and 7 Others
- Latest Funding Round: Post IPO, Feb 27, 2024, $*****
- Highlight: Acquired
4. AZTherapies
AZ Therapies is engaged in the discovery and development of small-molecule drugs for the treatment of Alzheimer's disease. Its drugs are aimed at blocking the formation of disease-causing aggregates of amyloid-beta (A-beta) protein oligomers and amyloid plaques. Its lead drug includes ALZT-OP1 which combines two small molecule drugs ALZT-OP1a & ALZT-OP1b to inhibit the formation of A-beta plaques and to treat inflammation respectively is being investigated for the treatment of Alzheimer's disease (Phase 3). ALZT-OP1a is also being developed to treat Post-Stroke Cognitive Impairment (Phase 2). The company is also developing ALZT-patch to deliver amyloid-beta plaque inhibitor; ALZT-QoL to increase neuronal activity to improve cognitive function, mood and social behavior (preclinical), and AZHALER-D, a single-use disposable inhaler.
Key facts about AZTherapies
- Founded Year: 2011
- Location: Boston (United States)
- Stage: Series C
- Total Funding till date: $131M
- Investors: Wexford Capital, Dolby Family Ventures and 14 Others
- Latest Funding Round: Series C, Sep 14, 2020, $*****
- Highlight: Editors' Pick
5. Epibone
Developer of patient‑specific bone and cartilage grafts. The company is offering custom‑shaped, living bone grafts engineered from a patient’s adipose‑derived mesenchymal stem cells and a CT scan of the defect. These are intended for complex bone‑reconstruction cases such as facial, craniofacial, or other skeletal defects.
Key facts about Epibone
- Founded Year: 2013
- Location: Brooklyn (United States)
- Stage: Series B
- Total Funding till date: $48.6M
- Employee Count: 22 as on Jul 31, 2026
- Investors: Hyperspeed, Partnership for New York City and 25 Others
- Latest Funding Round: Series B, Sep 02, 2025, $*****
- Highlight: Editors' Pick
Cavendish Impact Foundation's Year-on-Year Investment Trends
Its most recent first time investment was in Sandstone Diagnostics.Cavendish Impact Foundation's Investments by Stage
Cavendish Impact Foundation has made 1 investment in Series A stage with an average round size of $2.42M.Cavendish Impact Foundation's Investments by Sector
Cavendish Impact Foundation has a portfolio focused on Life Sciences. Notably, it has invested in 18 Tech companies, 15 Enterprise (B2B) companies, 5 Software companies and at least 4 companies focusing on Tech hardware.Cavendish Impact Foundation's Investments by Geography
Cavendish Impact Foundation has made most investments in United States (1).Cavendish Impact Foundation's recent investments
Cavendish Impact Foundation has not made any investment in 2026 so far.Here are the most recent investments by Cavendish Impact Foundation:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
May 10, 2019 | United States | Series A | 3288 |
IPOs and Publicly Listed companies in Cavendish Impact Foundation's Portfolio
1 of Cavendish Impact Foundation's portfolio company became public - Alto Neuroscience. It got listed on the New York Stock Exchange (NYSE), in Feb 2024 at marketcap of $409MHere are Cavendish Impact Foundation's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 02, 2024 | - | - | 5165 |
Acquired companies in Cavendish Impact Foundation's Portfolio
2 companies from Cavendish Impact Foundation's portfolio have been acquired. The most recent acquisition was Applied Therapeutics in Dec 2025 by Cycle Pharma for $*****.Here are Cavendish Impact Foundation's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 11, 2025 | - | - | 4372 | |
Aug 24, 2020 | - | - | 5934 |
Team profile of Cavendish Impact Foundation
Cavendish Impact Foundation has a team of 2 members including 2 Partners located in United States. Cavendish Impact Foundation's team does not sit on the board of any company as of now.Co-investors of Cavendish Impact Foundation
Over the past 7 years, 8 investors have co-invested in Cavendish Impact Foundation's portfolio companies. This includes funds and angels.
- Invested before Cavendish Impact Foundation: Astia, DPW Holdings and 5 others have invested in rounds before Cavendish Impact Foundation. There is 1 company where Astia has invested before Cavendish Impact Foundation and 1 company where DPW Holdings has invested before Cavendish Impact Foundation.
- Top Co-investors of Cavendish Impact Foundation: LabCorp entered a company along with Cavendish Impact Foundation.
